Log in
OTCMKTS:FSNUY

FRESENIUS SE &/S Stock Forecast, Price & News

$11.26
-0.41 (-3.51 %)
(As of 09/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$11.04
Now: $11.26▼
$11.26
50-Day Range
$11.16
MA: $11.57▼
$12.59
52-Week Range
$6.61
Now: $11.26▼
$14.22
Volume14,737 shs
Average Volume42,140 shs
Market Capitalization$25.06 billion
P/E Ratio12.37
Dividend Yield1.46%
Beta1.26
Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Read More
FRESENIUS SE &/S logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.27 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:FSNUY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.fresenius.com
Phone49-6172-6080

Debt

Debt-to-Equity Ratio0.80
Current Ratio1.11
Quick Ratio0.85

Price-To-Earnings

Trailing P/E Ratio12.37
Forward P/E Ratio12.11
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.66 billion
Price / Sales0.63
Cash Flow$2.17 per share
Price / Cash Flow5.19
Book Value$13.38 per share
Price / Book0.84

Profitability

EPS (Most Recent Fiscal Year)$0.94
Net Income$2.11 billion
Net Margins5.05%
Return on Equity6.78%
Return on Assets2.68%

Miscellaneous

Employees294,134
Outstanding Shares2,225,291,000
Market Cap$25.06 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$11.26
-0.41 (-3.51 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FSNUY News and Ratings via Email

Sign-up to receive the latest news and ratings for FSNUY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











FRESENIUS SE &/S (OTCMKTS:FSNUY) Frequently Asked Questions

How has FRESENIUS SE &/S's stock price been impacted by Coronavirus (COVID-19)?

FRESENIUS SE &/S's stock was trading at $10.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FSNUY shares have increased by 11.2% and is now trading at $11.26.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of FRESENIUS SE &/S?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FRESENIUS SE &/S in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for FRESENIUS SE &/S.

When is FRESENIUS SE &/S's next earnings date?

FRESENIUS SE &/S is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for FRESENIUS SE &/S.

How were FRESENIUS SE &/S's earnings last quarter?

FRESENIUS SE &/S (OTCMKTS:FSNUY) released its quarterly earnings data on Thursday, July, 30th. The company reported $0.20 earnings per share (EPS) for the quarter. The business had revenue of $9.82 billion for the quarter. FRESENIUS SE &/S had a net margin of 5.05% and a return on equity of 6.78%.
View FRESENIUS SE &/S's earnings history.

How often does FRESENIUS SE &/S pay dividends? What is the dividend yield for FRESENIUS SE &/S?

FRESENIUS SE &/S declared an annual dividend on Friday, July 10th. Shareholders of record on Tuesday, September 1st will be given a dividend of $0.16 per share on Thursday, September 10th. This represents a yield of 1.28%. The ex-dividend date is Monday, August 31st. This is a positive change from FRESENIUS SE &/S's previous annual dividend of $0.15.
View FRESENIUS SE &/S's dividend history.

Are investors shorting FRESENIUS SE &/S?

FRESENIUS SE &/S saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 4,000 shares, an increase of 263.6% from the August 15th total of 1,100 shares. Based on an average trading volume of 68,000 shares, the short-interest ratio is presently 0.1 days.
View FRESENIUS SE &/S's Short Interest.

Who are some of FRESENIUS SE &/S's key competitors?

Some companies that are related to FRESENIUS SE &/S include 3M (MMM), Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Penumbra (PEN), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC) and Hill-Rom (HRC).
View all competitors.

Who are FRESENIUS SE &/S's key executives?

FRESENIUS SE &/S's management team includes the following people:
  • Mr. Stephan Sturm, CEO & Chairman of Management Board - Fresenius Management SE (Age 56)
  • Ms. Rachel Clare Empey, CFO & Member of Management Board - Fresenius Management SE (Age 43)
  • Dr. Francesco De Meo, Member of Management Board - Fresenius Management SE (Age 55)
  • Dr. Jürgen Götz, Chief Legal & Compliance Officer & Labor Relations Director and Member of Management Board - GP (Age 55)
  • Dr. Ernst Wastler, Member of Management Board - Fresenius Management SE (Age 60)

What is FRESENIUS SE &/S's stock symbol?

FRESENIUS SE &/S trades on the OTCMKTS under the ticker symbol "FSNUY."

How do I buy shares of FRESENIUS SE &/S?

Shares of FSNUY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is FRESENIUS SE &/S's stock price today?

One share of FSNUY stock can currently be purchased for approximately $11.26.

How big of a company is FRESENIUS SE &/S?

FRESENIUS SE &/S has a market capitalization of $25.06 billion and generates $39.66 billion in revenue each year. The company earns $2.11 billion in net income (profit) each year or $0.94 on an earnings per share basis. FRESENIUS SE &/S employs 294,134 workers across the globe.

What is FRESENIUS SE &/S's official website?

The official website for FRESENIUS SE &/S is www.fresenius.com.

How can I contact FRESENIUS SE &/S?

FRESENIUS SE &/S's mailing address is Else-Kroner-Strasse 1, Bad Homburg 2M, 61352. The company can be reached via phone at 49-6172-6080 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.